NetWorth
LeaderPortfolio
Zhongru
Gan Zhongru
Rank #2354
CHINA•Healthcare•Pharmaceuticals, Self Made

Gan Zhongru

Net Worth
$1.728B
-0.2% (24h)
Gan Zhongru, a 77-year-old Chinese entrepreneur, is the co-founder and chairman of Gan & Lee Pharmaceuticals, a publicly traded company specializing in insulin and related products. His wealth stems from the pharmaceutical industry, and he is a self-made billionaire. Gan holds a Ph.D. from Michigan State University and previously worked at Merck before founding Gan & Lee in 1998. Gan & Lee focuses on research, development, production, and sales of recombinant insulin analogs and medical devices, holding a leading position in the Chinese diabetes market. Gan's career demonstrates a commitment to innovation and improving diabetes treatment through domestically developed insulin analogs.

How to read Gan Zhongru's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Gan Zhongru, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, Self Made, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $1.728B alongside global rank #2354, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (CHINA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Gan Zhongru was born in China and holds a Ph.D. from Michigan State University. Before embarking on his entrepreneurial journey, he gained experience working at Merck.

Rise to Success

In 1998, Gan Zhongru co-founded Gan & Lee Pharmaceuticals. The company, headquartered in Beijing, specializes in the development, production, and commercialization of insulin analogs and medical devices. Gan & Lee was the first Chinese company to master the technology for industrial-scale production of recombinant insulin analogs, establishing a leading position in the Chinese diabetes market. The company's industrial park covers approximately 200,000 square meters and employs over 5,500 people globally. Gan & Lee's success is also reflected in its collaborations with international partners like Sandoz, and its expansion into global markets.

Key Business Strategies

Gan & Lee focuses on innovation, producing the first Chinese domestic insulin analog. The company aims to become a trusted leader in the global pharmaceutical industry through innovative processes, business practices, and products. Gan & Lee has a mission to improve global health by providing valuable treatment options and reducing costs.

Philanthropy

Specific philanthropy amounts are not readily available in the search results, though the company's mission includes improving the quality of human life and improving global health. Gan & Lee is committed to providing scientific solutions to patients across the globe.

Career Timeline

2024

Named in Forbes China · Top 100 Most Influential Chinese Elite

Named to the "2023 Forbes China · Top 100 Most Influential Chinese Elite" list.

2020

Company went Public

Gan & Lee Pharmaceuticals went public on the Shanghai Stock Exchange.

1998

Founded Gan & Lee Pharmaceuticals

Cofounded Gan & Lee Pharmaceuticals, a company specializing in insulin analogs and medical devices.

Philanthropic Impact

HealthcareUnknown

Committed to improve global health

Gan & Lee aims to improve global health by providing valuable treatment options and reducing costs.

Key Business Ventures & Holdings

CompanyStakeValue
Gan & Lee Pharmaceuticals5.74%$0.1M

Net Worth History

In-Depth Analysis

Early Life

Gan Zhongru was born in China and holds a Ph.D. from Michigan State University. Before embarking on his entrepreneurial journey, he gained experience working at Merck.

Rise to Success

In 1998, Gan Zhongru co-founded Gan & Lee Pharmaceuticals. The company, headquartered in Beijing, specializes in the development, production, and commercialization of insulin analogs and medical devices. Gan & Lee was the first Chinese company to master the technology for industrial-scale production of recombinant insulin analogs, establishing a leading position in the Chinese diabetes market. The company's industrial park covers approximately 200,000 square meters and employs over 5,500 people globally. Gan & Lee's success is also reflected in its collaborations with international partners like Sandoz, and its expansion into global markets.

Key Business Strategies

Gan & Lee focuses on innovation, producing the first Chinese domestic insulin analog. The company aims to become a trusted leader in the global pharmaceutical industry through innovative processes, business practices, and products. Gan & Lee has a mission to improve global health by providing valuable treatment options and reducing costs.

Philanthropy

Specific philanthropy amounts are not readily available in the search results, though the company's mission includes improving the quality of human life and improving global health. Gan & Lee is committed to providing scientific solutions to patients across the globe.

Data Sources & Methodology

Figures for Gan Zhongru are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom